Find trials
Search tips

A Study Of Controlled Substance Agreements In A Palliative Medicine Practice

Overview

About this study

The purpose of this study is to assess patients’ understanding of the purpose and key components of the controlled substance agreement they signed in the palliative medicine clinic or hospital consultation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients who have signed an electronic or paper controlled substance agreement within the palliative medicine clinic.

  • Patients who are prescribed a controlled substance.

Exclusion Criteria: 

  • Patients who signed a CSA in the hospital.

  • Patients who did not sign a CSA. Patients who are no longer following with the palliative medicine clinic.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/18/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Molly Svendsen, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20598338

Mayo Clinic Footer